$Altamira Therapeutics Ltd.(CYTO)$ Wow, after performing DD this stock is so undervalued. Upcoming catalysts:1. AM-125 Phase 2 Completion (expected to close Dec 1, 2021) and data readout a month later (expected 1st week 2022, if not then Q1, 2022).2. DCGI nod on go ahead to conduct Bentrio trials in India. In-vitro efficacy against covid 19 and delta variant already established from previous PRs.3. Sales number indications from six south east markets and 3-4 european markets. (expected to be around 5-10 millions ?).4. Start of study around RNA therapeutics.5. 194 million volume from last session, tons of shorting I assume.6. Shorts hedging by putting money on 19 Nov calls 2.5, 5 and 7.5. I expect some action due to that.Please add if I have missed any !
精彩评论